CTAS options turn bullish days before earnings, even as shorts build

Options traders are betting on an upside surprise at CTAS earnings on October 27. The put-call ratio dropped to 0.787 on October 19, 2.3 standard deviations below its 20-day mean of 0.877, its most bullish reading in weeks.

That shift in options positioning stands against a short interest trend pointing the other way. Short positions have climbed roughly 13% over the past month to 3.12% of free float, the highest level since early September. Both signals are moving with conviction, and they are moving in opposite directions.

Shorts pile in, options traders push back

Short interest rose from about 11.1 million shares on October 8 to 12.6 million by October 16, a move that coincides with renewed attention on Cintas's pending acquisition of UniFirst. Bears appear to be positioning around execution risk tied to the deal. Yet the options market is not reading the same script. The PCR has fallen sharply from above 0.94 in late September, and the current Z-score of -2.27 marks a material shift in how options traders are sizing the risk around the print.

The borrow market gives no support to the short thesis at this stage. Availability stands at 3,347%, meaning there are roughly 33 shares available to borrow for every share currently shorted. Cost to borrow is 0.41%, low by any measure. Shorts face no structural squeeze pressure here.

UniFirst deal adds a mechanical buyer

The acquisition context carries a separate dimension. ORTEX forecasts an 80% probability that CTAS will see a share-count increase in the S&P 500 at the December quarterly review, tied to the UniFirst stock-and-cash takeover. If confirmed, index trackers would need to buy an estimated $376 million of CTAS stock, roughly 0.9 days of normal trading volume. The estimated announcement date is December 8, with a trade date around December 14. These are forecasts, not confirmed by the index provider.

Retail attention spikes

One other signal arrived this week. ORTEX Alt Data shows retail attention, measured as the average Z-score of daily Wikipedia pageviews and ORTEX stock page traffic against a 90-day baseline, jumped to 3.86 standard deviations above its own recent norms as of October 19. That is attention, not a revenue indicator, but the spike is the largest in the current dataset window and suggests a new cohort of individual investors is looking at the stock ahead of the earnings date.

Analysts who cover the name are broadly constructive. Argus Research raised its target to $240 and UBS to $235 following the last earnings print, against a current price of $212.30. Citigroup holds a Sell with a $181 target, the clearest dissenting voice in the coverage.

---

What to watch: the October 27 earnings release, specifically organic revenue growth and any update on the UniFirst deal timeline. Short interest at 3.12% of float is not extreme, but the month-long build makes the reaction to the print the cleaner signal of which side is right.